SG
RCKT icon

Sankala Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Sankala Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.74K Hold
828
– – ﹤0.01% 493
2026
Q1 		$3.21K Hold
828
– – ﹤0.01% 465
2025
Q4 		$4.15K Buy
+828
New +$2.83K ﹤0.01% 461

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sankala Group's RCKT Position: Q2 2026 in Review

Sankala Group held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 828 shares worth $2.74K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

Sankala Group first reported a position in RCKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.15K in Q4 2025. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Sankala Group held 828 shares of Rocket Pharmaceuticals worth $2.74K as of Q2 2026.
  • Sankala Group left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Sankala Group's portfolio in Q2 2026, its #493 holding.
  • Sankala Group first reported a position in Rocket Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Sankala Group's Rocket Pharmaceuticals position peaked at $4.15K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.